IHAM
IONS icon

Integral Health Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History

Integral Health Asset Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-500,000
Closed -$23.8M – 82
2024
Q2 		$23.8M Buy
+500,000
New +$20.5M 2.26% 13

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Integral Health Asset Management's IONS Position: Q1 2026 in Review

Integral Health Asset Management opened a new position in Ionis Pharmaceuticals (IONS) in Q1 2026: 125,000 shares worth $9.39M. The stake represents 0.45% of the portfolio and ranks #61 among its holdings. This is a return to the name: Integral Health Asset Management previously reported a position in IONS as recently as Q2 2024.

Integral Health Asset Management first reported a position in IONS in Q2 2024 and has held it in 2 quarters since. The position peaked at $11.9M in Q2 2024. 494 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • Integral Health Asset Management held 125,000 shares of Ionis Pharmaceuticals worth $9.39M as of Q1 2026.
  • Ionis Pharmaceuticals was a new Integral Health Asset Management position in Q1 2026.
  • Ionis Pharmaceuticals made up 0.45% of Integral Health Asset Management's portfolio in Q1 2026, its #61 holding.
  • Integral Health Asset Management first reported a position in Ionis Pharmaceuticals in Q2 2024 and has held it in 2 quarters since.
  • Integral Health Asset Management's Ionis Pharmaceuticals position peaked at $11.9M in Q2 2024.
  • 494 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Integral Health Asset Management's 13F filing for Q1 2026, filed 15 May 2026.